Rationale of the transfer
URINORM has long been used for treatments of gout and hyperuricemia for many patients as one of main products of Torii since 1979. Torii intends to focus on extending and maximizing values of the new products and transfer URINORM, based on the drastic reform of the drug price system.
Overview of the transfer
Products
URINORM Tablet 50mg
URINORM Tablet 25mg
Indication
Gout Hypertension accompanied by hyperuricemia
Launch
URINORM Tablet 50mg April, 1979
URINORM Tablet 25mg June, 1984
Sales 600 milliion yen in 2018
TOA EIYO will be responsible for not only providing and gathering URINORM's information but also supplying URINORM stably from
Torii will receive a consideration from TOA EIYO. TOA EIYO and Torii don't disclose the amount of consideration because of business circumstances.
Overview of TOA EIYO
Address 10-6,Hatchobori 3-chome,Chuo-ku,Tokyo,Japan
Representative President :
Business Manufacture and Sale of Pharmaceuticals
Capital
Foundation October,1943
Total Equity 54,555 million yenAs of
Total Assets 65,015 million yenAs of
Schedule
The date of Decision
The date of agreements
The date of transfer
Impact on Financial Performance
The effects of this transfer on the business performance of Torii's in this fiscal year will be immaterial.The effects on the business performance for the fiscal year ending
Contact:
Tel: +81-3-3231-6814
(C) 2019 Electronic News Publishing, source